9,825 results match your criteria: " Belgium; Center for Oxygen Research and Development[Affiliation]"

Heat capacity of periodically driven two-level systems.

Phys Rev E

August 2024

Department of Physics and Astronomy, KU Leuven 3000, Belgium.

We define the heat capacity for steady periodically driven systems and as an example we compute it for dissipative two-level systems where the energy gap is time-modulated. There, as a function of ambient temperature, the Schottky peak remains the dominant feature. Yet, in contrast with equilibrium, the quasistatic thermal response of a nonequilibrium system also reveals kinetic information present in the transition rates; e.

View Article and Find Full Text PDF
Article Synopsis
  • Advances in immuno-oncology have improved treatment for renal cell carcinoma, but patients with "primary refractory" disease have poor outcomes; our study found a 19% prevalence of this group among 1,709 metastatic clear cell patients across 72 centers in 22 countries.
  • The highest primary refractory rate was 27% with nivolumab/ipilimumab, while pembrolizumab/lenvatinib had the lowest at 10%; those classified as primary refractory only had a median survival of 7.6 months compared to 55.7 months for non-primary refractory patients.
  • Significant predictors of survival for primary refractory patients included factors like prior nephrectomy and presence of bone/brain metastases, highlighting the complex
View Article and Find Full Text PDF
Article Synopsis
  • The KEYNOTE-671 trial showed that adding pembrolizumab to neoadjuvant chemotherapy significantly enhanced event-free survival in patients with early-stage non-small-cell lung cancer (NSCLC).
  • The trial involved randomizing nearly 800 participants across 189 medical centers, comparing treatment with pembrolizumab plus chemotherapy against a placebo plus chemotherapy.
  • Results indicated that after 36 months, overall survival was higher in the pembrolizumab group (71%) compared to the placebo group (64%), suggesting a positive impact of the immunotherapy.
View Article and Find Full Text PDF
Article Synopsis
  • - The phase 3 study ENGOT-cx11/GOG-3047/KEYNOTE-A18 found that adding pembrolizumab to standard chemoradiotherapy significantly improved progression-free survival in patients with advanced cervical cancer during the first interim analysis.
  • - In this study, 1060 patients with high-risk cervical cancer were randomly assigned to receive either pembrolizumab or a placebo alongside chemoradiotherapy, with treatment outcomes evaluated at the second interim analysis.
  • - The primary outcomes measured were progression-free survival and overall survival, focusing on patient mortality, with safety being a secondary consideration.
View Article and Find Full Text PDF

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.

N Engl J Med

January 2025

From the Sandra and Edward Meyer Cancer Center (J.D.W.) and the Department of Medicine (J.D.W., M.A.P.), Weill Cornell Medicine, and Memorial Sloan Kettering Cancer Center (M.A.P.) - both in New York; Istituto Oncologico Veneto, IRCCS, Padua (V.C.-S.), European Institute of Oncology, IRCCS, Milan (P.Q.), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola (M.G.), University of Siena and the Center for Immuno-Oncology, University Hospital of Siena, Siena (M.M.), and Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples (P.A.A.) - all in Italy; Maria Sklodowska-Curie National Institute of Oncology, Warsaw, Poland (P.R.); Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); University Hospital Essen, the German Cancer Consortium, the National Center for Tumor Diseases-West, the Research Alliance Ruhr, Research Center One Health, and University Duisburg-Essen - all in Essen, Germany (D.S.); the College of Medicine, Swansea University, Swansea (J.W.), Bristol Myers Squibb, Uxbridge (A.N.), and the Royal Marsden Hospital, London (J.L.) - all in the United Kingdom; the Department of Dermatology, University of Zurich, Zurich, Switzerland (R.D.); University Health Network Princess Margaret Cancer Centre, Toronto (M.O.B.), and Cross Cancer Institute, University of Alberta, Edmonton (J.W.) - both in Canada; Tasman Oncology Research, Southport, QLD (A.G.H.), Westmead Hospital, Westmead, NSW (M.S.C.), Blacktown Hospital, Blacktown, NSW (M.S.C.), the Melanoma Institute Australia, University of Sydney (M.S.C., G.V.L.), Royal North Shore Hospital (G.V.L.), and Mater Hospital (G.V.L.), Sydney, and Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC (S.S.) - all in Australia; Aix-Marseille Université, Assistance Publique-Hôpitaux de Marseille, Marseille (C.G.-M.), and Université Paris Cité, Assistance Publique-Hôpitaux de Paris (AP-HP) Dermato-oncology, Clinical Investigation Center, the Cancer Institute, AP-HP Nord Paris Cité, INSERM Unité 976, and St. Louis Hospital, Paris (C.L.) - all in France; the University of Colorado Cancer Center, Aurora (T.M.); Rogel Cancer Center, University of Michigan, Ann Arbor (C.D.L.); Hospital General Universitario Gregorio Marañon, Madrid (I.M-R.); the Netherlands Cancer Institute, Amsterdam (J.B.A.G.H.); University Hospital Leuven and Leuven Cancer Institute, KU Leuven, Leuven, Belgium (P.S.); Bristol Myers Squibb, Princeton, NJ (C.R., M.A., M.P.B., W.W.); and Dana-Farber Cancer Institute, Boston (F.S.H.).

Background: Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with advanced melanoma. Given that patients with advanced melanoma are living longer than 7.5 years, longer-term data were needed to address new clinically relevant questions.

View Article and Find Full Text PDF

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.

N Engl J Med

December 2024

From Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, and Massachusetts General Hospital, Boston, MA (A.B.); the Department of Medical Oncology, Fudan University Shanghai Cancer Center, and the Department of Oncology, Shanghai Medical College, Fudan University, Shanghai (X.H.), and Harbin Medical University Cancer Hospital, Harbin (Q.Z.) - all in China; the Division of Medical Oncology, National Cancer Center Singapore, Singapore (R.D.); National Cancer Center Hospital, Tokyo (K.Y.); the Latin American Cooperative Oncology Group, Porto Alegre, Brazil (C.H.B.); Texas Oncology and US Oncology, Baylor University Medical Center, Dallas (J.A.O.); the Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium (H.W.); the Department of Medical Oncology, Institut Curie and Université Paris Cité, Paris (J.-Y.P.), Centre François Baclesse, Caen (C.L.), and the Department of Medical Oncology, Institut du Cancer de Montpellier, Université de Montpellier, INSERM Unité 1194, Montpellier (W.J.) - all in France; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (C.S.); the Department of Oncology, Santo Stefano Hospital, Azienda Unità Sanitaria Locale Toscana Centro, Prato (L.B.), and the European Institute of Oncology, IRCCS, and the Department of Oncology and Hematology-Oncology, University of Milan, Milan (G.C.) - all in Italy; the Division of Medical Oncology, Yonsei Cancer Center (J.S.), and the Department of Internal Medicine, Seoul National University Hospital (S.-A.I.) - both in Seoul, South Korea; Clinical Development, Late-Stage Development, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom (N.B., G.P.); and Biometrics Oncology, Late-Stage Development, Oncology Research and Development, AstraZeneca, Waltham, MA (J.K.).

Background: Outcomes in patients with hormone receptor-positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) after previous chemotherapy.

Methods: We conducted a phase 3, multicenter, open-label trial involving patients with hormone receptor-positive metastatic breast cancer with low HER2 expression (a score of 1+ or 2+ on immunohistochemical [IHC] analysis and negative results on in situ hybridization) or ultralow HER2 expression (IHC 0 with membrane staining) who had received one or more lines of endocrine-based therapy and no previous chemotherapy for metastatic breast cancer.

View Article and Find Full Text PDF

Background And Objective: The aim of the present report was to provide an overview of the use of the artificial urinary sphincter (AUS) in adult females with stress urinary incontinence (SUI) over the past 50 years.

Methods: A literature search was conducted in December 2022 and January 2023 using the MEDLINE and Embase databases, screening for randomized controlled trials (RCTs), prospective and retrospective series and reviews on AUS. Only articles published in English or French were included.

View Article and Find Full Text PDF

The formulation of multi-nutrient blocks based on low-cost and locally available browse feed resources can be a valid feeding strategy in Sub-Saharan Africa, where inadequate feed supply, both in quality and quantity, is a major constraint. We evaluated the four different inclusion percentages (M-0%, M-25%, M-35% and M-45%) of Moringa stenopetala leaf powder to multi-nutrient blocks on their change on blood metabolite of dairy cows under practical, ranging conditions. Multi-nutrient blocks with four inclusion rates of M.

View Article and Find Full Text PDF
Article Synopsis
  • The DESTINY-Breast12 study is the largest prospective trial examining the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer, including those with brain metastases (BMs).
  • In this study, T-DXd showed promising results, with a 12-month progression-free survival (PFS) of 61.6% for patients with BMs and an objective response rate (ORR) of 62.7% for those without BMs.
  • Adverse events were observed in both cohorts, with 51% of patients with BMs and 49% of those without experiencing grade 3 or higher side effects, indicating the need for careful monitoring
View Article and Find Full Text PDF

Background: Chronic lung infection with Pseudomonas aeruginosa is associated with increased exacerbations and mortality in people with bronchiectasis. The PROMIS-I and PROMIS-II trials investigated the efficacy and safety of 12-months of inhaled colistimethate sodium delivered via the I-neb.

Methods: Two randomised, double-blind, placebo-controlled trials of twice per day colistimethate sodium versus placebo were conducted in patients with bronchiectasis with P aeruginosa and a history of at least two exacerbations requiring oral antibiotics or one requiring intravenous antibiotics in the previous year in hospitals in Argentina, Australia, Belgium, Canada, France, Germany, Greece, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Spain, Switzerland, the UK, and the USA.

View Article and Find Full Text PDF

Purpose: Quantification of PSMA expression via PSMA PET is well-established, however quantification of PSMA via immunohistochemistry (IHC) is not standardized. Our aim was to determine the most optimal PSMA IHC scoring system to quantify PSMA expression with PSMA PET as reference standard.

Methods: Primary intermediate- and high-risk prostate cancer patients received an [F]PSMA-1007 PET/MRI followed by radical prostatectomy.

View Article and Find Full Text PDF

LRBA deficiency is an inborn error of immunity defined by autoimmunity, lymphoproliferation, recurrent infections, cytopenia, and inflammatory bowel disease. Despite recent advances in managing this disease with targeted biologic therapy, haematopoietic stem cell transplant (HSCT) remains the only cure. However, great variability exists between protocols used to transplant patients with LRBA deficiency.

View Article and Find Full Text PDF

Arbuscular mycorrhizal fungi (AMF) are totally dependent on a suitable host plant for their carbon resources. Here, we investigated under in vitro conditions, the impact of defoliation practices, i.e.

View Article and Find Full Text PDF
Article Synopsis
  • Scientists found that existing tools for analyzing single-cell data couldn't handle big data very well.
  • They created a new tool called scywalker that makes it easier to analyze long-read sequencing data from single cells or nuclei.
  • Scywalker can do many tasks in one go, like checking data quality and identifying different cell types, and it's available for anyone to use online.
View Article and Find Full Text PDF

A robust mouse model of HPIV-3 infection and efficacy of GS-441524 against virus-induced lung pathology.

Nat Commun

September 2024

KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Virology, Antiviral Drug & Vaccine Research Group, Leuven, Belgium.

Article Synopsis
  • HPIV-3 causes serious respiratory infections, and current small-animal models for studying it are inadequate, but AG129 mice effectively replicate the virus's effects.
  • Research showed that HPIV-3 targets specific lung cells and leads to significant lung damage, but does not spread between cohabitating infected and non-infected mice.
  • Treatment with GS-441524, a remdesivir component, decreased the virus in the lungs and improved lung health, suggesting AG129 mice are useful for testing new treatments and preventative measures for HPIV-3 in humans.
View Article and Find Full Text PDF

The use of fixed dose-combinations of antivirals with different mechanisms of action has proven key in the successful treatment of infections with HIV and HCV. For the treatment of infections with SARS-CoV-2 and possible future epi-/pandemic coronaviruses, it will be important to explore the efficacy of combinations of different drugs, in particular to avoid resistance development, such as in patients with immunodeficiencies. This work explores the effect of a combination of 3 broad-spectrum antiviral nucleosides on the replication of coronaviruses.

View Article and Find Full Text PDF

Focal Pulsed Field Ablation for Premature Ventricular Contractions: A Multicenter Experience.

Circ Arrhythm Electrophysiol

September 2024

Heart Rhythm Management Center, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel-Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Belgium (D.G.D.R., M.C.-F., L.P., A.A., E.S., G. Bala, J.S., G.V., A. Sorgente, C.A., I.O., A.D.M., G.-B.C., C.d.A., A. Sarkozy).

Background: Pulsed field ablation (PFA) is a novel technology for catheter-based atrial arrhythmia treatment. Evidence of its application for ventricular arrhythmia ablation is still limited. In this study, we describe the feasibility and efficacy of focal PFA for premature ventricular contraction (PVC) ablation.

View Article and Find Full Text PDF

Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study.

J Neurol Neurosurg Psychiatry

September 2024

Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia

Background: Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade, seronegative NMOSD remains less understood. This study aimed to evaluate the predictors of relapses and treatment responses in AQP4-IgG NMOSD and seronegative NMOSD.

View Article and Find Full Text PDF

Aims: Previous clinical studies on pulmonary vein isolation (PVI) with a radiofrequency balloon (RFB) reported safe and effective procedures using conventional ablation settings with 20/60 s RF delivery via posterior/anterior (PST/ANT) electrodes. The latest evidence suggests that reducing the application time to 15 s (s) on the posterior wall when facing the oesophageal region is as effective as applying 20 s. To prospectively assess whether reducing RF time on PST/ANT segments to 15/45 s can ensure sufficient quality of lesion metrics and compare the new shortened ablation settings with the conventional one in terms of safety, and effectiveness at 1-year.

View Article and Find Full Text PDF

Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections.

CPT Pharmacometrics Syst Pharmacol

November 2024

Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

Article Synopsis
  • * This study looked at the pharmacokinetics (how the drugs move and are processed in the body) of amodiaquine, desethylamodiaquine, and piperaquine in pregnant women during their second and third trimesters with uncomplicated malaria.
  • * Results showed that while amodiaquine's absorption increased with gestational age, the exposure to desethylamodiaquine and piperaquine in pregnant women was similar to that in non-pregnant women, indicating that dose adjustments are unnecessary for these patients.
View Article and Find Full Text PDF

Truncating genetic variants of , encoding the endosome recycling receptor SORLA, have been accepted as causal of Alzheimer's disease (AD). However, most genetic variants observed in are missense variants, for which it is complicated to determine the pathogenicity level because carriers come from pedigrees too small to be informative for penetrance estimations. Here, we describe three unrelated families in which the coding missense variant rs772677709, that leads to a p.

View Article and Find Full Text PDF

Gender and contemporary risk of adverse events in atrial fibrillation.

Eur Heart J

September 2024

Institute of Cardiovascular Sciences, University of Birmingham, Medical School, Vincent Drive, Birmingham B15 2TT, UK.

Article Synopsis
  • This study investigates how gender affects decision-making for oral anticoagulation in patients with atrial fibrillation (AF), using a large dataset of over 16 million patients from UK primary care between 2005-2020.
  • It found that in patients aged 40-75 without prior strokes, women had a lower adjusted rate of primary outcomes (death, ischemic stroke, or thromboembolism) compared to men, primarily due to lower mortality rates in women.
  • The study concludes that omitting gender from clinical risk scores could streamline the process of determining which AF patients should receive oral anticoagulation.
View Article and Find Full Text PDF

Effect of anionic groups in zwitterionic hydrophilic stationary phases on their chromatographic characteristics.

J Chromatogr A

October 2024

Institute of Pharmaceutical Analysis, College of Pharmacy/State Key Laboratory of Bioactive Molecules and Druggability Assessment/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou 510632, China. Electronic address:

The structure of zwitterion has great impact on the separation properties of zwitterionic hydrophilic stationary phases. To better understand the role of anionic groups of zwitterions, a novel carboxybetaine-based zwitterionic monolithic column was first prepared through thermo-initiated copolymerization of functional monomer (3-acrylamidopropyl)-dimethyl-(2-carboxymethyl) ammonium (CBAA) and crosslinker ethylene dimethacrylate (EDMA) within 100 μm ID capillary. The optimal poly(CBAA-co-EDMA) monolithic column exhibited satisfactory mechanical and chemical stability, good repeatability, high column efficiency (96,000 plates/m), and excellent separation performance for different classes of polar compounds (i.

View Article and Find Full Text PDF

Preclinical data have shown that Tb-labeled peptides targeting the somatostatin receptor are therapeutically more effective for peptide receptor radionuclide therapy than are their Lu-labeled counterparts. To further substantiate this enhanced therapeutic effect, we performed cellular dosimetry to quantify the absorbed dose to the cell nucleus and compared dose-response curves to evaluate differences in relative biological effectiveness in vitro. CA20948 cell survival was assessed after treatment with [Tb]Tb- and [Lu]Lu-DOTATATE (agonist) and with [Tb]Tb- and [Lu]Lu-DOTA-LM3 (antagonist) via a clonogenic assay.

View Article and Find Full Text PDF

Background: Antibody-mediated protection can depend on mechanisms varying from neutralization to Fc-dependent innate immune-cell recruitment. Adjuvanted vaccine development relies on a holistic understanding of how adjuvants modulate the quantity/titer and quality of the antibody response.

Methods: A Phase 2 trial (ClinicalTrials.

View Article and Find Full Text PDF